Banking & Finance  September 11, 2017

Array BioPharma sees success in clinical trials

BOULDER — Array BioPharma (Nasdaq: ARRY) experienced stock prices up 7 percent before the market opened following the announcement of positive data from clinical trials.

The third phase of clinical trials of its drug binimetinib combined with encorafenib showed positive results in patients with metastatic melanoma.

Earlier this summer, Array filed new drug applications to the Food and Drug Administration for the combination of the two drugs.

SPONSORED CONTENT

Business Cares: March 2024

WomenGive, a program of United Way of Larimer County, was started in Larimer County in 2006 as an opportunity for women in our community to come together to help other women.

At the time of publication, Array’s stock slid slightly, dropping from $11.82 when the market opened to $10.53 per share.

 

BOULDER — Array BioPharma (Nasdaq: ARRY) experienced stock prices up 7 percent before the market opened following the announcement of positive data from clinical trials.

The third phase of clinical trials of its drug binimetinib combined with encorafenib showed positive results in patients with metastatic melanoma.

Earlier this summer, Array filed new drug applications to the Food and Drug Administration for the combination of the two drugs.

At the time of publication, Array’s stock slid slightly, dropping from $11.82 when the market opened to $10.53 per share.

 

Sign up for BizWest Daily Alerts